The highly homologous kinases, Mek1 and Mek2, act downstream of Ras and Raf to activate extracellular signal-regulated kinase (ERK) mitogen-activated protein kinases. In epidermis, Ras and Raf promote hyperplasia; however, they act on multiple Mek-independent effectors, and the extent to which Meks can mediate these effects is unknown. To address this, we expressed inducible Meks in transgenic murine and human epidermis. Both Mek1 and Mek2 triggered ERK phosphorylation. Only Mek1, however, recapitulated Ras/Raf effects in increasing proliferation and integrin expression while suppressing differentiation, which are impacts characteristic of epidermal neoplasia. Furthermore, a kinase-dead Mek1 mutant incapable of phosphorylating ERK proteins retained ability to mediate Mek1-driven epidermal proliferation. Mek1 is thus sufficient to promote the proliferative epithelial phenotype in a manner independent of intact kinase function.
INTRODUCTION
The mitogen-activated protein kinase kinases [MAPKKs or MAP/ ERK kinases (Meks) also called MKK1 and MKK2] Mek1 and Mek2 operate downstream of Ras. Ras proteins display functional redundancy, with four canonical Ras GTPase proteins found in mammals: H-Ras, N-Ras, and two K-Ras splice variants, K-Ras4A and K-Ras4B. They signal via at least three major effector cascades initiated by binding of GTP-bound Ras to families of pathway effectors, including the Raf kinases, type I phosphatidyl-inositol-3 kinases (PI3Ks) and Ral guanine nucleotide exchange factors (RalGEF; Ref. 1) . These pathways operate differentially in discrete cell and tissue settings (1, 2) . The specific contributions of these three major Ras effector pathways are only beginning to be studied (2) , and their relative roles in tissue settings and homeostasis are unknown.
As with Ras, the three Raf isoforms, Raf1, A-Raf, and B-Raf, also exhibit features of genetic redundancy and can activate both Mek1 and Mek2. Mek1/2 are the only widely accepted Raf targets (3), although a Raf1 mutant incapable of activating Mek rescues the lethality seen with total Raf1 ablation, suggesting that other vital Raf functions might exist in addition to Mek activation (4) . Although other kinases such as MEKK1, Tpl-2, or mos can phosphorylate Mek, the major Mek activators in most cell types appear to be the Raf kinases (3) . Mek1 and Mek2 are evolutionarily conserved dual specificity kinases, which phosphorylate both threonine and tyrosine residues. Although a single Mek gene is found in Caenorhabditis elegans, Drosophila, and Xenopus, two Mek homologues exist in mammals, Mek1 and Mek2, which are Ͼ86% identical at the amino acid level (3, 5) . The only known enzymatic targets of Mek proteins are extracellular signal-regulated kinase (ERK) MAPKs, serine/threonine kinases involved in a multitude of cellular responses ranging from cytoskeletal changes to gene transcription (6) . Despite their similarity, the functions of Mek1 and Mek2 may not be entirely redundant, as evidenced by the death of Mek1 Ϫ/Ϫ mice in early gestation due to a placental vascularization defect (7) and the normality of Mek2 Ϫ/Ϫ mice (8) .
Stratified epithelial tissues such as the epidermis rely on a finely calibrated homeostatic balance between cell division in the undifferentiated basal cell layers and terminal differentiation in outer cell layers. In this setting, Ras and Raf had been previously observed to inhibit keratinocyte differentiation (9 -11) , although contradictory data have been presented (12) (13) (14) . Ras and Raf have recently been confirmed to support the basal layer cellular program by promoting three cardinal features of this tissue compartment: proliferative capacity; integrin expression; and suppressed differentiation (15, 16) . Whether any individual Ras downstream pathway mediates any of these effects on their own and the extent to which such effector action is conserved across species is unknown. The latter is an important issue because it has recently been described that Ras signaling may proceed via different pathways in murine versus human cell types (17) . Although a prior study suggested potential effects of Mek proteins on keratinocyte growth and differentiation in vitro, Mek function in vivo was not addressed (18) . Here, we demonstrate that Mek1 but not Mek2 is capable of inducibly stimulating proliferation and integrin expression while decreasing differentiation, thus promoting the hallmark features of the undifferentiated basal layer program of epidermal tissue. Moreover, this capacity is conserved between mice and humans and does not require an intact Mek1 kinase domain.
MATERIALS AND METHODS
Mek1/2 Constructs. To generate Mek retroviruses, a LZRS-based retroviral construct (19) modified with a Rfa cassette from the Gateway cloning system was used as a destination vector for all coding sequences, which were first cloned into pENTR1A (Life Technologies, Inc., Carlsbad, CA (21) , and kinase-dead Mek2 K101A (22) were subcloned into the BamHI site of pENTR1A vector. To generate either constitutively active or catalytically inactive, 4-hydroxytamoxifen (4OHT)-inducible Mek proteins, the appropriate Mek cDNAs were fused at their COOH termini to a mutated ligand-binding domain of the mouse estrogen receptor ␣ (ER-␣), which fails to bind estrogen but responds to 4OHT (23 Animal Studies and Cell Culture. Transgenic mice were generated on a FVB background using BssHI-linearized constructs. The following primers were used for PCR genotyping: 5Ј-CGTGCTGGTTATTGTGCTGTCTC-3Ј and 5Ј-GCTTCTTCTTGGGCATTTTGGAC-3Ј (for Mek1:ER) and 5Ј-TTTGAT-GGGGATGTTGGGGTGG-3Ј and 5Ј-ATGGTAGGGTTGATGGTGAGCG-3Ј (for Mek2:ER). Single transgenic F1-F3 mice were used in all experiments. To activate Mek1:ER and Mek2:ER in skin of adult mice, 1 mg of 4OHT dissolved in ethanol (10 mg/ml) was applied topically once/day to a shaved area of lower dorsal skin. Genetically matched wild-type littermates were used as controls in all experiments. Treated skin areas were harvested after either 5 days or 1 month of treatment, with the latter time point used to assess differentiation marker expression because of the ϳ4-week epidermal turnover cycle. For human cell culture and tissue studies, primary human keratinocytes were isolated and transduced with Mek retroviral vectors as previously described (26), with Ͼ99% gene transfer efficiency verified by immunofluorescence microscopy. Human epidermis was grafted to 6-week-old female CB.17 scid/scid mice as previously described (26), with three mice grafted and analyzed/group in duplicate independent experiments. Three to 4 weeks after surgery, grafted skin was treated daily with either 4OHT or ethanol control as described above.
Protein Expression Analysis. For immunoblotting, skin tissue and cell extract were homogenized in lysis buffer [20 mM Tris (pH 7.5), 150 mM NaCl, 1 mM EDTA, and 1% NP40] with protease inhibitors (Complete Mini EDTAfree; Roche, Indianapolis, IN) and phosphatase inhibitor mixture II (Sigma, St. Louis, MO). Twenty g of protein extract were loaded/lane and subjected to 10% SDS PAGE. The following antibodies were used: rabbit anti-MEK2 (Santa Cruz Biotechnology, Santa Cruz, CA); mouse anti-MEK1 and mouse anti-MEK2 (Transduction Laboratories); rabbit anti-ER-␣ (MC-20; Santa Cruz Biotechnology); rabbit anti-phospho-p44/42 MAPK and rabbit anti-totalp44/42 MAP kinase (Cell Signaling, Beverly, MA); mouse anti-␤-actin clone AC-15 (Sigma); donkey antirabbit IgG horseradish peroxidase (Amersham Biosciences, Piscataway, NJ); and sheep antimouse IgG horseradish peroxidase. Immunoblots were stripped with Restore Western Blot Stripping Buffer (Pierce, Rockford, IL). For immunostaining, 7 m of cryosections were allowed to air-dry then permeabilized with ice-cold 100% acetone for 10 min. Sections were blocked with 10% horse serum/PBS for 1 h, then incubated for 1 h at room temperature with primary antibody diluted in 2% horse serum/PBS followed by three washes with PBS and incubated for 30 -60 min with secondary antibodies diluted in 2% horse serum/PBS with 2 mg/ml Hoechst. After three washes with PBS, slides were mounted in Vectashield (Vector Laboratories Inc., Burlingame, CA) and examined under a Zeiss 100M Axiovert microscope. Immunostaining antibodies were purchased from the following sources: rabbit anti-keratin 6 and rabbit antimouse keratin 10 (Covance, Berkeley, CA); mouse antihuman keratin 10 (Chemicon, Temecula, CA); mouse anti-keratin 16 Ab-1 (Clone LL025; NeoMarkers, Fremont, CA), rat antimouse Ki-67 Clone TEC-3 (Dako, Carpinteria, CA), rabbit antihuman Ki-67 (LabVision, Fremont, CA); rat antimouse ␤1 integrin (Chemicon); mouse antihuman ␤1 integrin (Santa Cruz Biotechnology); rat anti-CD49f (␤4 integrin; Chemicon), rabbit antimouse involucrin (Covance); mouse antihuman involucrin clone S45 (Sigma); rabbit anti-phospho-p44/42 MAPK (Cell Signaling); rabbit anti-ER-␣ (MC-20; Santa Cruz Biotechnology); and goat antitumor growth factor (TGF)-␣ (R&D Systems, Minneapolis, MN). The following antibodies were purchased from Jackson ImmunoResearch Laboratories, Inc. (West Grove, PA): Cy3 donkey antirat IgG; Cy3 donkey antigoat IgG; Cy3 donkey antimouse IgG; and Cy3 donkey antirabbit IgG. TGF-␣ ELISA (Quantikine TGF-␣ ELISA; R&D Systems) was performed in accordance with the manufacturer's instructions. 
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RESULTS
To examine the role of Mek1/2 in epidermal homeostasis, we generated a panel of retroviral expression vectors as well as keratin 14 promoter-driven constructs for transgenic mouse generation. Wildtype as well as constitutively active and KD Mek1/2 mutant sequences were used. To regulate Mek function with 4-hydroxytamoxifen (4OHT), active and kinase-dead constructs were fused at their COOH termini to the mutant ligand binding domain of ER-␣. This approach has been used successfully to generate regulated Ras and Raf constructs (16, 23) . Expression of all Mek constructs, either after retrovector transduction in vitro (Fig. 1, A and B) or in transgenic murine epidermis (Fig. 2, A and B) , was verified by immunoblotting. Consistent with their catalytic function, constitutively active (CA) Mek1 and Mek2 both increased levels of phosphorylated ERK1/2, whereas KD mutants failed to induce this effect (Fig. 1, A and B) . Cells expressing CA-Mek:ER fusions (designated Mek:ER for the remainder of this work) displayed detectable basal levels of phospho-ERK1/2 that were increased in response to 4OHT while KD-Mek:ER fusions produced no ERK phosphorylation, either with or without 4OHT (Fig. 1, A and B) . Protein levels of both active and KD-Mek:ER fusion protein levels were consistently increased upon addition of 4OHT, as observed with other ER fusion proteins (16) .
To examine the effects of Mek activation in epidermal tissue, we generated three independent lines of transgenic mice for both Mek1:ER and Mek2:ER. Two genotypically confirmed Mek1:ER and three Mek2:ER lines displayed detectable fusion protein expression in 
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on April 14, 2017. © 2004 American Association for Cancer cancerres.aacrjournals.org Downloaded from skin extracts (Fig. 2, A and B) . Topical application of 4OHT increased levels of phosphorylated ERK1/2 in both Mek1:ER and Mek2:ER transgenics but not littermates and, in the case of Mek1:ER mice, produced clinical and histological evidence of epidermal hyperplasia in as few as 5 days (Fig. 2, C and D, and data not shown). Mek1:ER lines 12 and 13 displayed similar phenotypes, with line 12 changes more pronounced and thus chosen for more extensive study. Epidermal hyperplasia was fully established after 5 days of 4OHT and remained stable for a subsequent month of treatment, with no evidence of inflammation at either time point, as judged by lack of both inflammatory cell infiltration and increased markers such as tumor necrosis factor ␣ and interleukin 1␤ (data not shown). Mek1-induced changes were entirely reversed within 10 days after 4OHT cessation, as seen with regulated Ras and Raf (16) . In contrast, none of the Mek2:ER lines differed from nontransgenic controls in clinical or histological phenotype (data shown for line 59). Therefore, activating Mek1 but not Mek2 leads to hyperplasia in murine epidermis.
Induction of Ras and Raf in epidermis enhances features emblematic of the basal layer program of stratified epithelium (16) . To determine the extent to which Mek1 could recapitulate these effects, we next examined markers of proliferation as well as differentiation and integrin expression following Mek1 activation. Mek1 induction increased mitotic activity and enhanced expression of the proliferation-associated keratin 6 protein. It also elevated expression of ␤ 1 and ␤ 4 integrins (Fig. 3, A and B) . Epidermal differentiation markers, including involucrin and keratin 10, were suppressed (Fig. 3, A and  B) , although not entirely absent. No changes in cell death were observed, as judged by terminal deoxynucleotidyl transferase-mediated nick end labeling staining, and in contrast to Mek1, Mek2 induction showed no alterations in proliferation, integrins, or differentiation and was indistinguishable from untreated wild-type mice (data not shown). These findings indicate that, in murine tissue, Mek1 is sufficient to mediate the central epidermal effects of Ras and Raf in promoting the undifferentiated, proliferative program characteristic of the basal layer.
Human and murine mesenchymal cells can engage substantially different effector cascades downstream of Ras (17), so we next investigated whether Mek protein induction produced similar effects in human tissue. To do this, we used Mek retroviral expression vectors to regenerate human epidermis genetically engineered for constitutive and inducible alterations in Mek function. Retroviral transduction and human skin regeneration on immune deficient scid/scid mice were undertaken as previously described (26, 27) and resulting impacts on epidermal homeostasis examined. As observed in murine epidermis, both inducible and constitutive activation of active Mek1 in human tissue produced hyperplasia because of increased proliferation as well as augmented integrin expression and suppressed differentiation (Fig.  4A-D) . Moreover, active Mek2 induction failed to alter epidermal homeostasis by any of these measures but increased detectable phospho-ERK1/2 protein expression in epidermis (Fig. 4D) as it did in transgenic mice. Mek1 effects on epidermal growth and differentiation are thus congruent in both murine and human epidermal tissues and are not merely confined to one species.
Both Mek isoforms can activate their only known targets, ERK1 and ERK2, via phosphorylation of a Thr/Glu/Tyr motif. Our observation that activation of either Mek1 or Mek2 increased detection of nuclear phosphorylated ERK1/2 in epidermis yet only Mek1 induction altered epidermal homeostasis suggested that Mek1 protein kinase activity may be dispensable for its epidermal effects. To test this possibility, we expressed constitutive and 4OHT-inducible KD Mek constructs in genetically engineered human epidermis. Topical 4OHT application increased phosphorylated ERK1/2 in Mek1:ER-and Mek2:ER-engineered human tissue but not in KD-Mek1:ER tissue ( Supplementary Fig. 2 ) and KD-Mek2:ER tissue. Kinase-deficient Mek1, however, triggered substantial epidermal hyperplasia (Fig. 4A ) in a manner similar to active Mek1, whereas KD-Mek2 did not.
DISCUSSION
Here, we have shown that Mek1 is sufficient to promote integral features of the undifferentiated phenotype in epidermis. Despite its Ͼ86% amino acid sequence identity to Mek1, Mek2 exerted no effect in this setting, reminiscent of the marked differences seen in Mek1-and Mek2-knockout mice (7, 8) . Although activation of both Mek proteins increased levels of phosphorylated ERK1/2, only Mek1 altered epidermal homeostasis. Furthermore, a kinase-dead Mek1 mutant also induced hyperplasia. These data indicate that simple ERK phosphorylation is not sufficient to alter epidermal homeostasis and that an intact Mek1 kinase domain is dispensable for Mek1 effects in this setting. This suggests that Mek1 signaling in epidermis proceeds via a pathway that either diverges from the canonical Ras/Raf/Mek/ ERK cascade above the level of ERK MAPKs or is independent of ERK phosphorylation.
One potential mediator of Mek1 epidermal effects is TGF-␣, a protein that has been implicated in Ras epidermal effects on growth, differentiation, and neoplasia (28) . Although active Mek1 but not KD-Mek1 modestly increased TGF-␣ secretion by keratinocytes in vitro, so did Mek2, which does not drive epidermal hyperplasia (Supplementary Fig. 1A ). Moreover, neither Mek1 nor Mek2 produced detectable expression of TGF-␣ protein in vivo in either engineered epidermis or in Mek1-transgenic mice ( Supplementary Fig.  1B) ; therefore, TGF-␣ does not appear to represent a likely Mek1 effector in this setting. Examination of known Mek-interacting proteins such as KSR, MP1, and RKIP, which may act to enhance signaling specificity, may provide clues to the mechanism responsible for Mek1 impacts (29 -31) . Some of these proteins such as MP1 and p14 (32, 33) interact selectively with Mek1 but not Mek2 and thus constitute potential contributors to Mek1-selective effects in epidermis.
In addition to representing the major features of the undifferentiated tissue compartment of stratified epithelium, changes induced by Mek1 
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on April 14, 2017. © 2004 American Association for Cancer cancerres.aacrjournals.org Downloaded from are also observed in epidermal cancer, notably cutaneous squamous cell carcinoma. The finding that the Ras-MAPK cascade is up-regulated in a substantial proportion of human squamous cell carcinomas, even in the absence of primary mutations in RAS genes (27) , additionally supports efforts to explore Mek inhibition in squamous cell carcinoma. Our studies provide a rationale to further explore the effects of blocking Mek1 in squamous cell carcinoma and suggest that targeting Mek2 activity may not be a viable strategy for this cancer. Mek1 but not Mek2 is thus capable of promoting the undifferentiated, proliferative program in epidermis and may represent a candidate mediator of epidermal hyperproliferation characteristic of neoplastic skin disorders.
